January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk
TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopment-technology.com wraps-up the key headlines from January.
2016: The year's biggest Drug Development Technology stories
NIAID began a new HIV vaccine study in South Africa and Eli Lilly’s Phase III trial of Alzheimer disease drug failed. Drugdevelopment-technology wraps-up the key headlines from 2016.
November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial
UK’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November.
October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child
Eurocine Vaccines initiated a Phase I/II influenza vaccine study and a new study suggested in-vitro fertilisation increases the chances of conceiving a male child. Drugdevelopment-technology.com wraps up the key headlines from October 2016.
September's top stories: Oncternal begins TK216 trial, Medical cannabis trials begin in Canada
Oncternal Therapeutics began dosing patients in its Phase I clinical trial of TK216 to treat Ewing sarcoma and Tilray and University of British Columbia began patient enrolment in Canada’s first Phase II clinical trial of medical cannabis to treat post-traumatic stress disorder. Drugdevelopment-technology.com wraps up the key headlines from September 2016.